28
Jan
2010
07
Dec
2009
02
Nov
2009
02
Nov
2009
Arginetix, Inc.: Series B $4.6M
Posted in I - Series B, Q - 3Q09, R - MID ATLANTIC, X - Cardiology, XX - MD
Arginetix (Baltimore, MD) a preclinical-stage pharmaceutical company focused on the small molecule inhibition of arginase for pulmonary arterial hypertension, closed a $4.6M Series B financing. Participants include Quaker BioVentures, MedImmune Ventures, Red Abbey Venture Partners, Maryland Health Care Product Development Corp. and Acidophil.
22
Jun
2009
miRagen Therapeutics, Inc.: Series A $4M
Posted in I - Series A, Q - 2Q09, R - ROCKY MOUNTAIN, X - Cardiology, X - miRNA
miRagen Therapeutics (Boulder, CO) a preclinical-stage biopharmaceutical company focused on the development of miRNA therapeutics for cardiovascular and muscle diseases, closed a $4 Series B, bringing the total round financing to $12M. Participants include Boulder Ventures, Amgen Ventures, Broadview Ventures, The Peierls Foundation and Atlas Venture.
30
Mar
2009
Surface Logix, Inc.: Series E $15M
Posted in I - Series E, Q - 1Q09, R - NORTH EAST, X - Cardiology, X - Metabolism, XX - MA
Surface Logix (Brighton, MA) a clinical-stage small molecule company focused on metabolic and cardiovascular disease, closed a $15M Series E financing. Participants include ARCH Venture Partners, HBM BioVentures, Healthcare Focus, Intel Capital, Saudi Venture Development Co., Unilever Technology Ventures and Venrock.
30
Mar
2009
Ardian, Inc.: Series C $47M
Posted in I - Series C, Q - 1Q09, R - WEST, X - Cardiology, X - Device (Catheter), X - Renal, XX - CA
Ardian (Palo Alto, CA) a clinical-stage medical device company focused on catheter-based treatment for hypertension, chronic kidney disease and heart failure, closed a $47M Series C financing. Participants include Medtronic, Emergent Medical Partners, Advanced Technology Ventures, Morgenthaler Ventures and Split Rock Partners.
23
Mar
2009
Relypsa, Inc.: Series A $10M
Posted in I - Series A, Q - 1Q09, R - WEST, X - Cardiology, X - Hyperkalemia, XX - CA
Relypsa (Santa Clara, CA) a clinical-stage developer of a therapeutic for hyperkalemia in congestive heart failure patients closed a $10M Series A financing, the final tranche of the $43M round. Participants include 5AM Ventures, New Leaf Partners, Sprout Group, Delphi Ventures, CMEA Ventures and Mediphase Venture Partners.
25
Jan
2009
Crux Biomedical, Inc.: Series B $8M
Posted in I - Series B, Q - 1Q09, R - WEST, X - Cardiology, X - Device (Cardiology), XX - CA
Crux Biomedical (Menlo Park, CA) a clinical-stage is developing an implantable vascular device that offers potential improvement over existing inferior vena cava filter filters for treating and preventing pulmonary embolisms, closed an $8M Series B financing. Participants include Alloy Ventures and 1963 inventor of the balloon embolectomy catheter Thomas Fogarty.
25
Jan
2009
19
Jan
2009
7TM Pharma, A/S: Series E $15M
Posted in I - Series E, Q - 1Q09, R - INTERNATIONAL, X - Cardiology, X - Metabolism, X - Obesity
7TM Pharma (Denmark) a clinical-stage company focused on discovery and development of therapeutics for metabolic diseases including obesity and cardiovascular diseases, closed a $15M Series E financing. Participants include Novo, Alta Partners, LD Pensions, Index Ventures, Johnson & Johnson Development Corp, Sofinnova Capital, Lombard Odier Darier Hentsch & Cie, SR One, Global Life Science Ventures, [...]
04
Jan
2009
05
Dec
2008
Arete Therapeutics, Inc.: Series A $51
Posted in I - Series A, Q - 4Q08, R - WEST, X - Cardiology, X - Inflammation, X - Metabolism
Arete Therapeutics (Hayward, CA) clinical-stage biotechnology company developing soluble epoxide hydrolase inhibitor small molecule drugs for the treatment of cardiovascular, metabolic and inflammatory diseases, closed a $51M Series A financing. Participants include Frazier Healthcare Ventures, Alta Partners, Burrill & Co., Three Arch Partners, and Altitude Life Science Ventures.
OnBioVC PARTNERS
-
